{"id":"https://openalex.org/W2017082986","doi":"https://doi.org/10.1038/sj.bjc.6603419","title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","display_name":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","publication_year":2006,"publication_date":"2006-10-10","ids":{"openalex":"https://openalex.org/W2017082986","doi":"https://doi.org/10.1038/sj.bjc.6603419","mag":"2017082986","pmid":"https://pubmed.ncbi.nlm.nih.gov/17031397","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2360568"},"language":"en","primary_location":{"id":"doi:10.1038/sj.bjc.6603419","doi":"https://doi.org/10.1038/sj.bjc.6603419","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603419","pdf_url":null,"source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1038/sj.bjc.6603419","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036620887","display_name":"Ignacio Dur\u00e1n","orcid":"https://orcid.org/0000-0001-8571-7163","observed_orcids":["https://orcid.org/0000-0001-8571-7163"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"I Duran","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, ON, Canada M5G 2M9"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, ON, Canada M5G 2M9","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069279240","display_name":"Jeremy S. Kortmansky","orcid":"https://orcid.org/0009-0002-4820-5809","observed_orcids":["https://orcid.org/0009-0002-4820-5809"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Kortmansky","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, USA","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101785908","display_name":"Deepti Singh","orcid":"https://orcid.org/0000-0002-0173-4220","observed_orcids":["https://orcid.org/0000-0002-0173-4220"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D Singh","raw_affiliation_strings":["University of Chicago, Chicago, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, USA","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026047065","display_name":"Hal W. Hirte","orcid":"https://orcid.org/0000-0003-2888-4146","observed_orcids":["https://orcid.org/0000-0003-2888-4146"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"H Hirte","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112135140","display_name":"Walter Kocha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"W Kocha","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102766368","display_name":"Glenwood D. Goss","orcid":"https://orcid.org/0000-0002-5122-9011","observed_orcids":["https://orcid.org/0000-0002-5122-9011"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"G Goss","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032075908","display_name":"Lyly Le","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"L Le","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072712459","display_name":"Amit M. Oza","orcid":"https://orcid.org/0000-0002-9510-8641","observed_orcids":["https://orcid.org/0000-0002-9510-8641"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"A Oza","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054326085","display_name":"Trudey Nicklee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"T Nicklee","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030417585","display_name":"Jcm Ho","orcid":"https://orcid.org/0000-0003-4499-5284","observed_orcids":["https://orcid.org/0000-0003-4499-5284"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"J Ho","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087537382","display_name":"Diana C. Birle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"D Birle","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047689900","display_name":"Gregory R. Pond","orcid":"https://orcid.org/0000-0003-1033-0882","observed_orcids":["https://orcid.org/0000-0003-1033-0882"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"G R Pond","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5098367615","display_name":"D Arboine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"D Arboine","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015598221","display_name":"Janet Ellen Dancey","orcid":"https://orcid.org/0000-0001-8356-0019","observed_orcids":["https://orcid.org/0000-0001-8356-0019"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Dancey","raw_affiliation_strings":["National Cancer Institute, Bethesda, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Institute, Bethesda, USA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006711579","display_name":"Sarit Aviel\u2010Ronen","orcid":"https://orcid.org/0000-0002-9660-7979","observed_orcids":["https://orcid.org/0000-0002-9660-7979"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"S Aviel-Ronen","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073362806","display_name":"Ming\u2010Sound Tsao","orcid":"https://orcid.org/0000-0002-9160-5405","observed_orcids":["https://orcid.org/0000-0002-9160-5405"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"M-S Tsao","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011309882","display_name":"David William Hedley","orcid":"https://orcid.org/0000-0003-1323-2655","observed_orcids":["https://orcid.org/0000-0003-1323-2655"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"D Hedley","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000204204","display_name":"Lillian L. Siu","orcid":"https://orcid.org/0000-0002-3500-0540","observed_orcids":["https://orcid.org/0000-0002-3500-0540"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"L L Siu","raw_affiliation_strings":["Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, 610 University Avenue, Suite 5-718, Toronto, M5G 2M9, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]},{"raw_affiliation_string":"Department of Medical Oncology and Hematology, Princess Margaret Hospital Phase II Consortium, Toronto, Canada","institution_ids":["https://openalex.org/I2802654988"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5000204204"],"corresponding_institution_ids":["https://openalex.org/I2802654988"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":14.5893,"has_fulltext":true,"cited_by_count":321,"citation_normalized_percentile":{"value":0.99417896,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":100},"biblio":{"volume":"95","issue":"9","first_page":"1148","last_page":"1154"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/temsirolimus","display_name":"temsirolimus","score":1.0},{"id":"https://openalex.org/keywords/neuroendocrine-carcinoma","display_name":"neuroendocrine carcinoma","score":0.9779999852180481},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.8259999752044678},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8489999771118164},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8180000185966492},{"id":"https://openalex.org/keywords/phosphorylated-mtor","display_name":"phosphorylated mTOR","score":0.7149999737739563},{"id":"https://openalex.org/keywords/phosphorylated-akt","display_name":"phosphorylated Akt","score":0.9110000133514404},{"id":"https://openalex.org/keywords/ribosomal-protein-s6-phosphorylation","display_name":"S6 phosphorylation","score":0.9229999780654907},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.8190000057220459},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6710000038146973},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8069999814033508},{"id":"https://openalex.org/keywords/drug-response","display_name":"drug response","score":0.3019999861717224}],"concepts":[{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.9880037307739258},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.634749174118042},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.610144317150116},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.552990734577179},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5458928942680359},{"id":"https://openalex.org/C2777921159","wikidata":"https://www.wikidata.org/wiki/Q32089","display_name":"Sirolimus","level":2,"score":0.5414012670516968},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.5307172536849976},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4585241675376892},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.434578001499176},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42543715238571167},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.22691547870635986},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.22604483366012573},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.13793465495109558},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.11193591356277466},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002276","descriptor_name":"Carcinoid Tumor","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002276","descriptor_name":"Carcinoid Tumor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002276","descriptor_name":"Carcinoid Tumor","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010766","descriptor_name":"Phosphorylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D038601","descriptor_name":"Ribosomal Protein S6","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1038/sj.bjc.6603419","doi":"https://doi.org/10.1038/sj.bjc.6603419","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603419","pdf_url":null,"source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2360568","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2360568/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2360568/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},{"id":"pmid:17031397","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17031397","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1038/sj.bjc.6603419","doi":"https://doi.org/10.1038/sj.bjc.6603419","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603419","pdf_url":null,"source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G3827620274","display_name":null,"funder_award_id":"53912","funder_id":"https://openalex.org/F4320334506","funder_display_name":"Canadian Institutes of Health Research"},{"id":"https://openalex.org/G5068780872","display_name":null,"funder_award_id":"STP53912","funder_id":"https://openalex.org/F4320334506","funder_display_name":"Canadian Institutes of Health Research"},{"id":"https://openalex.org/G7514466679","display_name":null,"funder_award_id":"N01-CO-124001","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G984818956","display_name":null,"funder_award_id":"N01 CM 17107","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320334506","display_name":"Canadian Institutes of Health Research","ror":"https://ror.org/01gavpb45"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2017082986.pdf","grobid_xml":"https://content.openalex.org/works/W2017082986.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W33615505","https://openalex.org/W1668086213","https://openalex.org/W1771569409","https://openalex.org/W1969629557","https://openalex.org/W1974932725","https://openalex.org/W1980780628","https://openalex.org/W1988609792","https://openalex.org/W1993421446","https://openalex.org/W2021012077","https://openalex.org/W2045173749","https://openalex.org/W2076597476","https://openalex.org/W2098176107","https://openalex.org/W2100030097","https://openalex.org/W2107276199","https://openalex.org/W2112001957","https://openalex.org/W2113365503","https://openalex.org/W2125859598","https://openalex.org/W2126783165","https://openalex.org/W2128879260","https://openalex.org/W2139248078","https://openalex.org/W2147394591","https://openalex.org/W2165147224","https://openalex.org/W2240351742","https://openalex.org/W2249288343","https://openalex.org/W2257439960","https://openalex.org/W2274323124","https://openalex.org/W2327663281","https://openalex.org/W2337432642","https://openalex.org/W2339290868","https://openalex.org/W2414496343","https://openalex.org/W4234566037","https://openalex.org/W4238567307"],"related_works":["https://openalex.org/W2070572192","https://openalex.org/W7099818130","https://openalex.org/W2590343087","https://openalex.org/W1975442922","https://openalex.org/W3045403856","https://openalex.org/W2979795996","https://openalex.org/W2921322908","https://openalex.org/W2118672029","https://openalex.org/W7099479259","https://openalex.org/W2962848184"],"abstract_inverted_index":{"Standard":[0],"cytotoxic":[1],"treatments":[2],"for":[3,55,89,153],"neuroendocrine":[4,34],"tumours":[5],"have":[6,177],"been":[7],"associated":[8,169],"with":[9,32,39,170],"limited":[10],"activity":[11,179],"and":[12,26,65,81,92,108,130,161,180],"remarkable":[13],"toxicity.":[14],"A":[15],"phase":[16],"II":[17],"study":[18],"was":[19,99],"designed":[20],"to":[21,59,176],"evaluate":[22],"the":[23,136],"efficacy,":[24],"safety":[25],"pharmacodynamics":[27],"of":[28,47,50,85,118,123,138,144,149],"temsirolimus":[29,86],"in":[30,158,163,187],"patients":[31,38,124],"advanced":[33,40,188],"carcinoma":[35],"(NEC).":[36],"Thirty-seven":[37],"progressive":[41],"NEC":[42],"received":[43],"intravenous":[44],"weekly":[45],"doses":[46],"25":[48],"mg":[49],"temsirolimus.":[51],"Patients":[52],"were":[53,87,168],"evaluated":[54],"tumour":[56,77],"response,":[57],"time":[58],"progression":[60],"(TTP),":[61],"overall":[62],"survival":[63],"(OS)":[64],"adverse":[66],"events":[67],"(AE).":[68],"Twenty-two":[69],"archival":[70],"specimens,":[71],"as":[72,74,121],"well":[73],"13":[75],"paired":[76],"biopsies":[78],"obtained":[79],"pretreatment":[80],"after":[82,166],"2":[83],"weeks":[84],"assessed":[88],"potential":[90],"predictive":[91],"correlative":[93],"markers.":[94],"The":[95,113],"intent-to-treat":[96],"response":[97],"rate":[98,111],"5.6%":[100],"(95%":[101],"CI":[102],"0.6-18.7%),":[103],"median":[104],"TTP":[105],"6":[106],"months":[107],"1-year":[109],"OS":[110],"71.5%.":[112],"most":[114],"frequent":[115],"drug-related":[116],"AE":[117],"all":[119],"grades":[120],"percentage":[122],"were:":[125],"fatigue":[126],"(78%),":[127],"hyperglycaemia":[128],"(69%)":[129],"rash/desquamation":[131],"(64%).":[132],"Temsirolimus":[133,174],"effectively":[134],"inhibited":[135],"phosphorylation":[137],"S6":[139],"(P=0.02).":[140],"Higher":[141],"baseline":[142],"levels":[143],"pmTOR":[145,164],"(phosphorylated":[146],"mammalian":[147],"target":[148],"rapamycin)":[150],"(P=0.01)":[151],"predicted":[152],"a":[154],"better":[155],"response.":[156],"Increases":[157],"pAKT":[159],"(P=0.041)":[160],"decreases":[162],"(P=0.048)":[165],"treatment":[167],"an":[171],"increased":[172],"TTP.":[173],"appears":[175],"little":[178],"does":[181],"not":[182],"warrant":[183],"further":[184],"single-agent":[185],"evaluation":[186],"NEC.":[189],"Pharmacodynamic":[190],"analysis":[191],"revealed":[192],"effective":[193],"mTOR":[194],"pathway":[195],"downregulation.":[196]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":16},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":21},{"year":2013,"cited_by_count":34},{"year":2012,"cited_by_count":33}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}